Advances in EGFR-directed therapy in head and neck cancer

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 2, 2011, Pages 454-466

  Numico, Gianmauro ^a   Silvestris, Nicola ^b   Russi, Elvio Grazioso ^c  

^a Aosta Hospital   (Italy)

^b Istituto Oncologico   (Italy)

^c A O S Croce e Carle   (Italy)

Author keywords

Chemoradiotherapy; EGFR; Head and neck Cancer; Review

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROCORTISONE; HYDROXYUREA; LAPATINIB; MAGNESIUM; MAGNESIUM SULFATE; MATUZUMAB; METHOTREXATE; MINOCYCLINE; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PLACEBO; PLATINUM; TETRACYCLINE; VANDETANIB; ZALUTUMUMAB; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG TOLERABILITY; DRY SKIN; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEART FAILURE; HUMAN; HYPOMAGNESEMIA; HYPOPHARYNX CANCER; INDUCTION CHEMOTHERAPY; INTERSTITIAL LUNG DISEASE; LARYNX CANCER; MAGNESIUM BLOOD LEVEL; MAINTENANCE THERAPY; METASTASIS; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PRURITUS; PUSTULE; QUALITY OF LIFE; RADIATION DERMATITIS; RASH; SEPSIS; SKIN EXFOLIATION; SKIN PRURITUS; SKIN TOXICITY; STOMACH PERFORATION; STOMATITIS; SUPERINFECTION; THROMBOCYTOPENIA; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG HYPERSENSITIVITY; HEAD AND NECK TUMOR; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG HYPERSENSITIVITY; EXANTHEMA; HEAD AND NECK NEOPLASMS; HUMANS; LUNG DISEASES, INTERSTITIAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIODERMATITIS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79955953374     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s164     Document Type: Article

References (81)

1. Haddad RI, Shin DM. Recent Advances in Head and Neck Cancer. N Engl J Med 359(11):1143-1154 (2008)
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 371: 1695-1709 (2008)
3. Choong N, Vokes E. Expanding role of the medical oncologist in the management of head and neck cancer. CA Cancer J Clin 58 :32-53 (2008)
4. Kim S, Grandis JR, Rinaldo A, Takes RP, Ferlito A. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 30: 667-674 (2008)
5. Brockstein B, Lacouture M, Agulnik M. The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw 6 :696-706 (2008)
6. Harari PM, Wheeler DL, Grandis J.R. Molecular target approaches in head and neck cancer: epidermal growth factor receptor and beyond. Semin Radiat Oncol 19: 63-68 (2009)
7. Egloff AM, Grandis J.R. Targeting epidermal growth factor receptor and SRC pathways in head and neck cancer. Semin. Oncol 35 :286-297 (2008)
8. Gold KA, Lee H, Kim ES. Targeted therapies in squamous cell carcinoma of the head and neck. Cancer 115: 922-935 (2009)
9. Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6: 742-750 (2008)
10. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz- Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25: 2171-2177 (2007)
11. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS. Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol 23: 5578-5587 (2005)
12. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes- Funes H, Hitt R, Gascon P, Amellal N, Harstrick A, Eckardt A. Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. J Clin Oncol 23: 5568-5577 (2005)
13. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin. Oncol 23: 8646-8654 (2005)
14. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer H, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127 (2008)
15. Mesía R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer H, Cupissol D, De Raucourt D, Benasso M, Koralewski P, Delord J, Bokemeyer C, Curran D, Gross A, Vermorken JB. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck [Internet]. Ann Oncol [cited 2010 Giu 28 ]
16. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW. Phase I Study of Anti-Epidermal Growth Factor Receptor Antibody Cetuximab in Combination With Radiation Therapy in Patients With Advanced Head and Neck Cancer. J Clin Oncol 19: 3234-3243 (2001)
17. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 354: 567-578 (2006)
18. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28 (2010)
19. Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 3: 5 (2008)
20. Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357: 514-515 (2007)
21. Russi EG, Merlano MC, Comino A, Numico G. Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. AlteRCC Italian Trial): in regard to Macmillan et al. (Int J Radiat Oncol Biol Phys 2007;68:864-872). Int J Radiat Oncol Biol Phys 69: 638-639 (2007)
22. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 43: 35-45 (2007)
23. Lefebvre J, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, de Raucourt D, Bardet E, Tuchais C, Calais G, Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC). Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol (Meeting Abstracts) 27(15S): 6010 (2009)
24. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24: 1072-1078 (2006)
25. Langer CJ, Lee JW, Patel UA, Shin DM, Argiris AE, Quon H, Ridge JA, Forastiere AA. Preliminary analysis of ECOG 3303: Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 26 (15S): 6006 (2008)
26. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated- accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck [Internet]. Ann Oncol [cited 2010 Giu 29 ] Available from: http://www.ncbi.nlm.nih.gov.bvs.cilea.it/pubmed/20427347 (2010)
27. Kao J, Policarpio L, Teng M, Burri R, Genden E, Packer S. Phase II trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and intensity modulated radiation therapy (IMRT) for locally advanced head and neck cancer. J Clin Oncol (Meeting Abstracts) 27(15S): 6014 (2009)
28. Merlano M. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative? Oncologist 11(2): 146-151 (2006)
29. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensitymodulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 21: 342-347 (2010)
30. Machiels JH, Subramanian S, Ruzsa A, Repassy G, Lifrenko I, Flygare A, Sorensen P, Ehrnrooth E, Baadsgaard O, Clement PM. An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE). J Clin Oncol (Meeting Abstracts) 28(18S):LBA5506 (2010)
31. Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J
32. Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, Mulén B, Wilkinson B, de Armas EL, Pérez K, Pineda I, Frómeta M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 9: 343-349 (2010)
33. Stewart JSW, Cohen EEW, Licitra L, Van Herpen CML, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Varella-Garcia M, Ghiorghiu S, Hargreaves L, Armour A, Speake G, Swaisland A, Vokes EE. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27: 1864-1871 (2009)
34. Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol (Meeting Abstracts) 27(15S): 6011 (2009)
35. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, Harrison L, Quon H, Dancey J, Baron A, Said S, Eckhardt SG, Raben D. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 25: 4880-4886 (2007)
36. Ahmed SM, Cohen EE, Haraf DJ, Stenson KM, Blair E, Brockstein BE, Lin S, Lester E, Dekker A, Williams R, Vokes EE. Updated results of a phase II trial integrating gefitinib (G) into concurrent chemoradiation (CRT) followed by G adjuvant therapy for locally advanced head and neck cancer (HNC). J Clin Oncol (Meeting Abstracts) 25(18S): 6028 (2007)
37. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85 (2004)
38. Siu LL, Soulieres D, Chen EX, Pond GR, Chin SF, Francis P, Harvey L, Klein M, Zhang W, Dancey J, Eisenhauer EA, Winquist E. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 25: 2178-2183 (2007)
39. Kim ES, Kies MS, Glisson BS, Tsao A, Ginsberg LE, Holsinger FC, Burke BJ, Truong M, Papadimitrakopoulou VA, Lippman SM. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol (Meeting Abstracts) 25 (18S): 6013 (2007)
40. Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord J. Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma. Clin Cancer Res 13:7086-7092 (2007)
41. Vokes EE, Cohen EEW, Mauer AM, Karrison TG, Wong SJ, Skoog-Sluman LJ, Kozloff MF, Dancey J, Dekker A. A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC). J Clin Oncol (Meeting Abstracts) 23 (16S): 5504 (2005)
42. Abidoye OO, Cohen EE, Wong SJ, Kozloff MF, Nattam SR, Stenson KM, Blair EA, Day S, Dancey JE, Vokes EE. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 24 (18S): 5568 (2006)
43. Harrington KJ, Berrier A, Robinson M, Remenar E, Housset M, Hurtado de Mendoza F, Compton N, Lau M, Legenne P, Kumar R. Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol (Meeting Abstracts) 28 (15S): 5505 (2010)
44. Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VWY, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis J.R. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 27: 1235-1242 (2009)
45. Ang KK, Berkey BA, Tu X, Zhang H, Katz R, Hammond EH, Fu KK, Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62: 7350-7356 (2002)
46. Numico G, Russi EG, Colantonio I, Lantermo RA, Silvestris N, Vitiello R, Comino A, Abrate M, Zavattero C, Melano A, Merlano M. EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res 30: 671-676 (2010)
47. Agulnik M, da Cunha Santos G, Hedley D, Nicklee T, Dos Reis PP, Ho J, Pond GR, Chen H, Chen S, Shyr Y, Winquist E, Soulieres D, Chen EX, Squire JA, Marrano P, Kamel-Reid S, Dancey J, Siu LL, Tsao MS. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 25: 2184-2190 (2007)
48. Licitra L, Rolland F, Bokemeyer C, Remenar E, Kienzer H, Stoerkel S, Scheid S, Stroh C, Mesia R. Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in firstline R/M SCCHN. J Clin Oncol (Meeting Abstracts) 27 (15S): 6005 (2009)
49. Hitt R, Martín P, Hidalgo M. Cetuximab in squamous cell carcinoma of the head and neck. Future Oncol 2: 449-457 (2006)
50. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu C, Ganul V, Roh J, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373: 1525-1531 (2009)
51. Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park, N.Y.) 21 (11 Suppl 5): 17-21 (2007)
52. Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 128: 1365-1374 (2008)
53. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113: 847-853 (2008)
54. Su X, Lacouture ME, Jia Y, Wu S. Risk of high-grade skin rash in cancer patients treated with Cetuximab - an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 77: 124-133 (2009)
55. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113: 847-853 (2008)
56. Scope A, Agero ALC, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25: 5390-5396 (2007)
57. Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre- Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28: 1351-1357 (2010)
58. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16: 1425-1433 (2005)
59. Dent P, Reardon DB, Park JS, Bowers G, Logsdon C, Valerie K, Schmidt-Ullrich R. Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10: 2493-2506 (1999)
60. Russi EG, Merlano MC, Comino A, Numico G. Ultrathin hydrocolloid dressing in skin damaged from alternating radiotherapy and chemotherapy plus cetuximab in advanced head and neck cancer (G.O.N.O. AlteRCC Italian Trial): in regard to Macmillan et al. (Int J Radiat Oncol Biol Phys 2007;68:864-872). Int J Radiat Oncol Biol Phys 69: 638-639 (2007)
61. Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55: 657-670 (2006)
62. Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 56: 317-326 (2007)
63. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 115: 1286-1299 (2009)
64. Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol 85: 171 (2007)
65. Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, Locati L, Maillard S, Ozsahin M, Pfeffer R, Robertson AG, Langendijk JA, Budach W. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90: 166-171 (2009)
66. Merlano MC, Numico G, Russi EG, Benasso M, Colantonio I, Vigna Taglianti R, Lanzilotta L, Vigo V, Bacigalupo A. Cetuximab (C-mab) and chemo-radiation (CTRT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study. J Clin Oncol (Meeting Abstracts) 25 (18S): 6043 (2007)
67. Bernier J, Bonner J, Vermorken JB, Bensadoun R, Dummer R, Giralt J, Kornek G, Hartley A, Mesia R, Robert C, Segaert S, Ang KK. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19: 142-149 (2008)
68. Chung CH, Mirakhur B, Chan E, Le Q, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109-1117 (2008)
69. Siena S, Glynne-Jones R, Adenis A, Thaler J, Preusser P, Aguilar EA, Aapro MS, Loos AH, Esser R, Wilke H. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 116: 1827-1837 (2010)
70. George TJ, Laplant KD, Walden EO, Davis AB, Riggs CE, Close JL, George SN, Lynch JW. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. J Support Oncol 8: 72-77 (2010)
71. Lenz H. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12: 601-609 (2007)
72. Tejpar S, Piessevaux H, Claes K, Piront P, Hoenderop JGJ, Verslype C, Van Cutsem E. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: A prospective study. Lancet Oncol 8: 387-394 (2007)
73. Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, Soria JC. Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol 73: 213- 219 (2010)
74. Fakih M. Anti-EGFR monoclonal antibody-induced hypomagnesaemia. Lancet Oncol 8: 366-367 (2007)
75. Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME. Association of cetuximab with adverse pulmonary events in cancer patients: A comprehensive review. J Exp Clin Cancer Res 28:113 (2009)
76. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2866-2872 (2006)
77. Knoedler MK, Gauler T, Matzdorff A, Jordan O, Schroeder M, Gruenwald V, Dietz A, Arnold D, Hennemann B, Keilholz U. Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J Clin Oncol (Meeting Abstracts) 27 (15S): 6048 (2009)
78. Cohen EEW, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987 (2003)
79. Wheeler RH, Jones D, Sharma P, Davis RK, Spilker H, Boucher K, Leachman S, Grossman D, Salzman K, Akerley W. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca). J Clin Oncol (Meeting Abstracts) 23 (16S): 5531 (2005)
80. Cohen EEW, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11: 8418-8424 (2005)
81. Kirby AM, A'Hern RP, D'Ambrosio C, Tanay M, Syrigos KN, Rogers SJ, Box C, Eccles SA, Nutting CM, Harrington KJ. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94: 631-636 (2006)